Tuesday, January 19, 2016 9:13:57 AM
[Rockwell Medical Announces Two Triferic® Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 ? May 1, 2016 in Boston, MA
Ticker Symbol: U:RMTI
WIXOM, Mich., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that two Triferic abstracts have been selected by the National Kidney Foundation (NKF) for presentation at their Spring Clinical Meetings to be held April 27 ? May 1, 2016 at the Hynes Convention Center, Boston, MA. Triferic is the Company’s iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
The following abstracts have been accepted to be printed in the American Journal of Kidney Disease and for poster presentation at the NKF meetings:
Triferic Maintains Hemoglobin and Iron Balance Long Term: Open-Label Phase III Extension Studies
Pharmacology of Triferic in Chronic HD Patients
About Triferic
Triferic is a unique iron replacement product that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. Triferic is added to the bicarbonate concentrate on-site at the dialysis clinic. Once in dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Triferic delivers sufficient iron to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin). Please visit www.triferic.com or call Rockwell Medical at 800-449-3353 for more information.
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin).
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information./b]
Recent RMTI News
- Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States • Business Wire • 04/17/2024 10:00:00 AM
- Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024 • Business Wire • 04/16/2024 10:00:00 AM
- Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda • Business Wire • 04/04/2024 10:00:00 AM
- Rockwell Medical Named 'Great Place to Work' for Second Year in a Row • Business Wire • 03/25/2024 10:00:00 AM
- Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023 • Business Wire • 03/21/2024 10:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:31:02 PM
- Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024 • Business Wire • 02/08/2024 11:00:00 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:56:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:36:07 PM
- Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund • Business Wire • 01/08/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 11:52:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 11:15:54 AM
- Rockwell Medical Announces Third Quarter 2023 Results • Business Wire • 11/14/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2023 10:18:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2023 10:17:25 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2023 10:16:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2023 10:16:02 AM
- Rockwell Medical Names Jesse Neri as Senior Vice President, Finance • Business Wire • 10/18/2023 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:15:59 AM
- Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors • Business Wire • 10/17/2023 10:00:00 AM
- Rockwell Medical to Release Third Quarter 2023 Results on Tuesday, November 14, 2023 • Business Wire • 10/16/2023 10:00:00 AM
- Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care • Business Wire • 10/03/2023 10:00:00 AM
- Rockwell Medical Enters into 3-Year Product Purchase Agreement with Sanderling Renal Services; Expands Distribution Capabilities Westward into Utah • Business Wire • 09/28/2023 10:00:00 AM
- Rockwell Medical Enters into Products Purchase Agreement with its Largest Customer, Enhancing Relationship through 2024 • Business Wire • 09/21/2023 10:30:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM